Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05095363 · ClinicalTrials.gov registry record · NA

Palliative Care Planner (PCplanner)

A NA study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by Duke University.

Completed
Registry status
NA
Development phase
43
Enrollment target
1
Study location

NCT05095363 is a NA study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease that has completed, run by Duke University. The registered enrollment target is 43 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05095363, a NA study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
43 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to determine the feasibility, acceptability, and evidence for clinical impact of a mobile app-based program called Palliative Care Planner (PCplanner) in addressing needs and promoting advance care planning discussions among patients with idiopathic pulmonary fibrosis and their clinicians.

Interventions

  • BEHAVIORAL PCplanner

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2022-03-16
Est. Completion 2023-03-31
Phase NA

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT05095363

The ClinicalTrials.gov registry entry for NCT05095363 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (94% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which PCplanner is the first listed.

NCT05095363 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05095363 about?

NCT05095363 is a clinical study titled "Palliative Care Planner (PCplanner)". The purpose of this research study is to determine the feasibility, acceptability, and evidence for clinical impact of a mobile app-based program called Palliative Care Planner (PCplanner) in addressing needs and promoting advance care planning discussions among patients with idiopathic pulmonary fi...

What is the current status of trial NCT05095363?

This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2022-03-16. Estimated completion is 2023-03-31.

What conditions does trial NCT05095363 study?

This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease.

What interventions are being tested in trial NCT05095363?

The interventions under investigation include: PCplanner (BEHAVIORAL).

Who is sponsoring clinical trial NCT05095363?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05095363 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Idiopathic Pulmonary Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.